Non-interventional safety study on the tolerability and safety of octagam® 5%, octagam® 10% and panzyga®

Trial Profile

Non-interventional safety study on the tolerability and safety of octagam® 5%, octagam® 10% and panzyga®

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Feb 2017

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Autoimmune disorders; Immunodeficiency disorders
  • Focus Adverse reactions
  • Sponsors Octapharma
  • Most Recent Events

    • 25 Jan 2017 Planned number of patients changed from 2000 to 5000.
    • 25 Jan 2017 Planned End Date changed from 31 Dec 2017 to 31 Dec 2019.
    • 16 Feb 2016 Planned End Date changed from 31 Dec 2015 to 31 Dec 2017, according to ISRCTN: Current Controlled Trials record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top